Elgan Pharma Ltd.
Elgan Pharma Ltd.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA | Digestive System Diseases, Nutritional and Metabolic Diseases, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease | Recruiting | Phase 2 | 2026-04-09 | NCT05904626 | |
| Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants | Digestive System Diseases, Nutritional and Metabolic Diseases, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease | Recruiting | Phase 3 | 2026-01-23 | NCT05670951 |